O	0	5	Runx2	Runx2	NN	B-NP
O	6	9	and	and	CC	I-NP
O	10	13	MYC	MYC	NN	I-NP
O	14	25	collaborate	collaborate	NN	I-NP
O	26	28	in	in	IN	B-PP
B-Cancer	29	37	lymphoma	lymphoma	NN	B-NP
O	38	49	development	development	NN	I-NP
O	50	52	by	by	IN	B-PP
O	53	64	suppressing	suppress	VBG	B-VP
O	65	74	apoptotic	apoptotic	JJ	B-NP
O	75	78	and	and	CC	I-NP
O	79	85	growth	growth	NN	I-NP
O	86	92	arrest	arrest	NN	I-NP
O	93	101	pathways	pathway	NNS	I-NP
O	102	104	in	in	FW	B-ADVP
O	105	109	vivo	vivo	FW	I-ADVP
O	109	110	.	.	.	O

O	112	119	Members	Member	NNS	B-NP
O	120	122	of	of	IN	B-PP
O	123	126	the	the	DT	B-NP
O	127	131	Runx	Runx	NN	I-NP
O	132	135	and	and	CC	I-NP
O	136	139	MYC	MYC	NN	I-NP
O	140	148	families	family	NNS	I-NP
O	149	153	have	have	VBP	B-VP
O	154	158	been	be	VBN	I-VP
O	159	169	implicated	implicate	VBN	I-VP
O	170	172	as	as	IN	B-PP
O	173	186	collaborating	collaborate	VBG	B-VP
O	187	196	oncogenes	oncogene	NNS	B-NP
O	196	197	.	.	.	O

O	198	201	The	The	DT	B-NP
O	202	211	mechanism	mechanism	NN	I-NP
O	212	214	of	of	IN	B-PP
O	215	219	this	this	DT	B-NP
O	220	226	potent	potent	JJ	I-NP
O	227	240	collaboration	collaboration	NN	I-NP
O	241	243	is	be	VBZ	B-VP
O	244	254	elucidated	elucidate	VBN	I-VP
O	255	257	in	in	IN	B-PP
O	258	262	this	this	DT	B-NP
O	263	268	study	study	NN	I-NP
O	269	271	of	of	IN	B-PP
O	272	277	Runx2	Runx2	NN	B-NP
O	277	278	/	/	SYM	B-NP
O	278	281	MYC	MYC	NN	I-NP
O	282	286	mice	mouse	NNS	I-NP
O	286	287	.	.	.	O

O	288	290	As	As	IN	B-SBAR
O	291	296	shown	show	VBN	B-VP
O	297	307	previously	previously	RB	B-ADVP
O	307	308	,	,	,	O
O	309	316	ectopic	ectopic	JJ	B-NP
O	317	327	expression	expression	NN	I-NP
O	328	330	of	of	IN	B-PP
O	331	336	Runx2	Runx2	NN	B-NP
O	337	339	in	in	IN	B-PP
O	340	343	the	the	DT	B-NP
B-Organ	344	350	thymus	thymus	NN	I-NP
O	351	356	leads	lead	VBZ	B-VP
O	357	359	to	to	TO	B-PP
O	360	361	a	a	DT	B-NP
B-Cancer	362	375	preneoplastic	preneoplastic	JJ	I-NP
O	376	381	state	state	NN	I-NP
O	382	389	defined	define	VBN	B-VP
O	390	392	by	by	IN	B-PP
O	393	395	an	an	DT	B-NP
O	396	408	accumulation	accumulation	NN	I-NP
O	409	411	of	of	IN	B-PP
B-Cell	412	417	cells	cell	NNS	B-NP
O	418	422	with	with	IN	B-PP
O	423	425	an	an	DT	B-NP
O	426	434	immature	immature	JJ	I-NP
O	435	444	phenotype	phenotype	NN	I-NP
O	445	448	and	and	CC	O
O	449	450	a	a	DT	B-NP
O	451	454	low	low	JJ	I-NP
O	455	468	proliferative	proliferative	JJ	I-NP
O	469	473	rate	rate	NN	I-NP
O	473	474	.	.	.	O

O	475	477	We	We	PRP	B-NP
O	478	481	now	now	RB	B-ADVP
O	482	486	show	show	VBP	B-VP
O	487	491	that	that	IN	B-SBAR
O	492	493	c	c	NN	B-NP
O	493	494	-	-	HYPH	B-NP
O	494	497	MYC	MYC	NN	I-NP
O	498	512	overexpression	overexpression	NN	I-NP
O	513	515	is	be	VBZ	B-VP
O	516	526	sufficient	sufficient	JJ	B-ADJP
O	527	529	to	to	TO	B-PP
O	530	536	rescue	rescue	NN	B-NP
O	537	550	proliferation	proliferation	NN	I-NP
O	551	554	and	and	CC	O
O	555	557	to	to	TO	B-VP
O	558	565	release	release	VB	I-VP
O	566	569	the	the	DT	B-NP
O	570	585	differentiation	differentiation	NN	I-NP
O	586	591	block	block	NN	I-NP
O	592	599	imposed	impose	VBN	B-VP
O	600	602	by	by	IN	B-PP
O	603	608	Runx2	Runx2	NN	B-NP
O	608	609	.	.	.	O

O	610	618	Analysis	Analysis	NN	B-NP
O	619	621	of	of	IN	B-PP
O	622	627	Runx2	Runx2	NN	B-NP
O	627	628	-	-	HYPH	O
O	628	638	expressing	express	VBG	B-VP
B-Cancer	639	648	lymphomas	lymphoma	NNS	B-NP
O	649	656	reveals	reveal	VBZ	B-VP
O	657	658	a	a	DT	B-NP
O	659	671	consistently	consistently	RB	I-NP
O	672	675	low	low	JJ	I-NP
O	676	680	rate	rate	NN	I-NP
O	681	683	of	of	IN	B-PP
O	684	693	apoptosis	apoptosis	NN	B-NP
O	693	694	,	,	,	O
O	695	697	in	in	IN	B-PP
O	698	706	contrast	contrast	NN	B-NP
O	707	709	to	to	TO	B-PP
B-Cancer	710	719	lymphomas	lymphoma	NNS	B-NP
O	720	722	of	of	IN	B-PP
O	723	726	MYC	MYC	NN	B-NP
O	727	731	mice	mouse	NNS	I-NP
O	732	737	which	which	WDT	B-NP
O	738	741	are	be	VBP	B-VP
O	742	747	often	often	RB	B-ADVP
O	748	754	highly	highly	RB	B-ADJP
O	755	764	apoptotic	apoptotic	JJ	I-ADJP
O	764	765	.	.	.	O

O	766	769	The	The	DT	B-NP
O	770	773	low	low	JJ	I-NP
O	774	783	apoptosis	apoptosis	NN	I-NP
O	784	793	phenotype	phenotype	NN	I-NP
O	794	796	is	be	VBZ	B-VP
O	797	805	dominant	dominant	JJ	B-ADJP
O	806	808	in	in	IN	B-PP
B-Cancer	809	814	Runx2	Runx2	NN	B-NP
I-Cancer	814	815	/	/	SYM	B-NP
I-Cancer	815	818	MYC	MYC	NN	I-NP
I-Cancer	819	825	tumors	tumor	NNS	I-NP
O	825	826	,	,	,	O
O	827	837	indicating	indicate	VBG	B-VP
O	838	842	that	that	IN	B-SBAR
O	843	848	Runx2	Runx2	NN	B-NP
O	849	856	confers	confer	VBZ	B-VP
O	857	858	a	a	DT	B-NP
O	859	865	potent	potent	JJ	I-NP
O	866	874	survival	survival	NN	I-NP
O	875	884	advantage	advantage	NN	I-NP
O	885	887	to	to	TO	B-PP
O	888	891	MYC	MYC	NN	B-NP
O	891	892	-	-	HYPH	O
O	892	902	expressing	express	VBG	B-VP
B-Cell	903	908	tumor	tumor	NN	B-NP
I-Cell	909	914	cells	cell	NNS	I-NP
O	914	915	.	.	.	O

O	916	919	The	The	DT	B-NP
O	920	924	role	role	NN	I-NP
O	925	927	of	of	IN	B-PP
O	928	931	the	the	DT	B-NP
O	932	935	p53	p53	NN	I-NP
O	936	943	pathway	pathway	NN	I-NP
O	944	946	in	in	IN	B-PP
B-Cancer	947	952	Runx2	Runx2	NN	B-NP
I-Cancer	952	953	/	/	SYM	B-NP
I-Cancer	953	956	MYC	MYC	NN	I-NP
I-Cancer	957	963	tumors	tumor	NNS	I-NP
O	964	967	was	be	VBD	B-VP
O	968	976	explored	explore	VBN	I-VP
O	977	979	on	on	IN	B-PP
O	980	981	a	a	DT	B-NP
B-Cell	982	985	p53	p53	NN	I-NP
I-Cell	986	998	heterozygote	heterozygote	NN	I-NP
O	999	1009	background	background	NN	I-NP
O	1009	1010	.	.	.	O

O	1011	1023	Surprisingly	Surprisingly	RB	B-ADVP
O	1023	1024	,	,	,	O
O	1025	1035	functional	functional	JJ	B-NP
O	1036	1039	p53	p53	NN	I-NP
O	1040	1043	was	be	VBD	B-VP
O	1044	1052	retained	retain	VBN	I-VP
O	1053	1055	in	in	FW	B-ADVP
O	1056	1060	vivo	vivo	FW	I-ADVP
O	1060	1061	,	,	,	O
O	1062	1066	even	even	RB	B-ADVP
O	1067	1072	after	after	IN	B-PP
O	1073	1088	transplantation	transplantation	NN	B-NP
O	1088	1089	,	,	,	O
O	1090	1097	whereas	whereas	IN	O
O	1098	1107	explanted	explante	VBN	B-NP
B-Cell	1108	1113	tumor	tumor	NN	I-NP
I-Cell	1114	1119	cells	cell	NNS	I-NP
O	1120	1129	displayed	display	VBD	B-VP
O	1130	1135	rapid	rapid	JJ	B-NP
O	1136	1142	allele	allele	NN	I-NP
O	1143	1147	loss	loss	NN	I-NP
O	1148	1150	in	in	FW	B-ADVP
O	1151	1156	vitro	vitro	FW	I-ADVP
O	1156	1157	.	.	.	O

O	1158	1161	Our	Our	PRP$	B-NP
O	1162	1169	results	result	NNS	I-NP
O	1170	1174	show	show	VBP	B-VP
O	1175	1179	that	that	IN	B-SBAR
O	1180	1185	Runx2	Runx2	NN	B-NP
O	1186	1189	and	and	CC	I-NP
O	1190	1193	MYC	MYC	NN	I-NP
O	1194	1202	overcome	overcome	VBP	B-VP
O	1203	1211	distinct	distinct	JJ	B-NP
O	1212	1213	"	"	``	I-NP
O	1213	1217	fail	fail	NN	I-NP
O	1217	1218	-	-	HYPH	I-NP
O	1218	1222	safe	safe	JJ	I-NP
O	1222	1223	"	"	''	I-NP
O	1224	1233	responses	response	NNS	I-NP
O	1234	1237	and	and	CC	O
O	1238	1242	that	that	IN	B-SBAR
O	1243	1248	their	their	PRP$	B-NP
O	1249	1258	selection	selection	NN	I-NP
O	1259	1261	as	as	IN	B-PP
O	1262	1275	collaborating	collaborate	VBG	B-VP
O	1276	1281	genes	gene	NNS	B-NP
O	1282	1284	is	be	VBZ	B-VP
O	1285	1288	due	due	JJ	B-ADJP
O	1289	1291	to	to	TO	B-PP
O	1292	1297	their	their	PRP$	B-NP
O	1298	1305	ability	ability	NN	I-NP
O	1306	1308	to	to	TO	B-VP
O	1309	1319	neutralize	neutralize	VB	I-VP
O	1320	1324	each	each	DT	B-NP
O	1325	1330	other	other	JJ	I-NP
O	1330	1331	'	'	``	I-NP
O	1331	1332	s	s	JJ	I-NP
O	1333	1341	negative	negative	JJ	I-NP
O	1342	1348	growth	growth	NN	I-NP
O	1349	1355	effect	effect	NN	I-NP
O	1355	1356	.	.	.	O

O	1357	1368	Furthermore	Furthermore	RB	B-ADVP
O	1368	1369	,	,	,	O
O	1370	1373	the	the	DT	B-NP
O	1374	1379	Runx2	Runx2	NN	I-NP
O	1379	1380	/	/	SYM	B-NP
O	1380	1383	MYC	MYC	NN	I-NP
O	1384	1395	combination	combination	NN	I-NP
O	1396	1405	overcomes	overcome	VBZ	B-VP
O	1406	1409	the	the	DT	B-NP
O	1410	1421	requirement	requirement	NN	I-NP
O	1422	1425	for	for	IN	B-PP
O	1426	1433	genetic	genetic	JJ	B-NP
O	1434	1446	inactivation	inactivation	NN	I-NP
O	1447	1449	of	of	IN	B-PP
O	1450	1453	the	the	DT	B-NP
O	1454	1457	p53	p53	NN	I-NP
O	1458	1465	pathway	pathway	NN	I-NP
O	1466	1468	in	in	FW	B-ADVP
O	1469	1473	vivo	vivo	FW	I-ADVP
O	1473	1474	.	.	.	O

